-

01:10:05 PM

HALO Stock News

HALO - Halozyme Therapeutics Inc.

08/31/23 8:30 AM

Nasdaq : HALO

conferences

Halozyme to Present at Upcoming Investor Conferences

Halozyme Therapeutics, Inc. today announced that Dr. Helen Torley, president and chief executive officer, is scheduled to present and host investor meetings at the following investor conferences. Details on the presentations are as follow:.

RHEA-AI

neutral

08/08/23 4:01 PM

Nasdaq : HALO

earnings

HALOZYME REPORTS SECOND QUARTER 2023 FINANCIAL AND OPERATING RESULTS

Revenue Increased 45% YOY to $221.0 million; GAAP Diluted EPS of $0.56 and Non-GAAP Diluted EPS of $0.74 1. Royalty Revenue Increased 31% YOY to Record $111.7 million. "Our strong second quarter results with record revenue of $221 million and non-GAAP EPS of $0.74 were complemented with significant commercial and clinical advancements with our ENHANZE...

RHEA-AI

neutral

07/25/23 8:30 AM

Nasdaq : HALO

conferencesearnings

Halozyme To Report Second Quarter 2023 Financial and Operating Results

Halozyme Therapeutics, Inc. today announced it will release its second quarter 2023 financial and operating results on Tuesday, August 8, 2023, following the close of trading. Halozyme will host a conference call on Tuesday, August 8, 2023 at 4:30 p.m. ET/1: 30 p.m. PT to discuss the results.

RHEA-AI

neutral

07/17/23 1:15 AM

Nasdaq : HALO

Positive Topline Data Reported from argenx's ADHERE Study of VYVGART® Hytrulo with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

Halozyme Therapeutics, Inc. today announced that argenx reported positive topline data from the ADHERE study evaluating VYVGART ® Hytrulo with ENHANZE ® in adults with chronic inflammatory demyelinating polyneuropathy. The study met its primary endpoint demonstrating a significantly lower risk of relapse with...

RHEA-AI

neutral

07/13/23 1:15 AM

Nasdaq : HALO

clinical trial

Positive Results Announced from Phase 3 OCARINA II Trial Evaluating Roche's OCREVUS® (ocrelizumab) with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Multiple Sclerosis

Halozyme Therapeutics, Inc. today announced that Roche's Phase 3 OCARINA II trial evaluating OCREVUS ® with ENHANZE ® as a twice a year 10- minute subcutaneous injection, met its primary and secondary endpoints in patients with relapsing forms of multiple sclerosis or primary progressive MS. OCREVUS subcutaneous...

RHEA-AI

neutral

06/20/23 6:30 PM

Nasdaq : HALO

fda approval

Halozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo With ENHANZE® for Subcutaneous Use in Generalized Myasthenia Gravis

Halozyme Therapeutics, Inc. today announced that argenx received U.S. Food and Drug Administration approval for VYVGART ® Hytrulo injection with ENHANZE ® for subcutaneous use for the treatment of generalized...

RHEA-AI

neutral

06/06/23 8:30 AM

Nasdaq : HALO

conferences

Halozyme to Present at the Goldman Sachs 44th Annual Global Healthcare Conference

Halozyme Therapeutics, Inc. today announced that Dr. Helen Torley, president and chief executive officer, will present at the Goldman Sachs 44th Annual Global Healthcare Conference on Tuesday, June 13, 2023, at 8 a.m. Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the...

RHEA-AI

neutral

05/09/23 4:01 PM

Nasdaq : HALO

earnings

HALOZYME REPORTS FIRST QUARTER 2023 FINANCIAL AND OPERATING RESULTS

Revenue Increased 38% YOY to $162.1 million; GAAP Diluted Earnings per Share of $0.29 and Non-GAAP Diluted Earnings per Share of $0.47 1. Royalty Revenue Increased 43% YOY to $99.6 million. Reiterating 2023 Revenue Guidance of $815-$845 million, Representing 23-28% YOY Growth; EBITDA of $415-$440 million, Representing > 30% YOY Growth 1.

RHEA-AI

neutral

05/03/23 8:30 AM

Nasdaq : HALO

conferences

Halozyme to Present at Upcoming Investor Conferences

Halozyme Therapeutics, Inc. today announced that Dr. Helen Torley, president and chief executive officer, is scheduled to present and host investor meetings at the following investor conferences. Details of the presentations are as follow:.

RHEA-AI

neutral

04/25/23 8:30 AM

Nasdaq : HALO

conferences

Halozyme To Report First Quarter 2023 Financial and Operating Results

Halozyme will host a conference call on Tuesday, May 9, 2023 at 4:30 p.m. ET/ 1:30 p.m. PT to discuss the results. A live webcast and replay of the conference call will also be available through the "Investors" section of Halozyme's corporate website at www.halozyme.com. Having touched more than 700,000 patient lives in post-marketing use in five...

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 Next

HALO Data

IndustryBiological Product (except Diagnostic) Manufacturing
Websitehttps://www.halozyme.com/
Security nameHalozyme Therapeutics Inc.
SectorManufacturing
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Biological Product (except Diagnostic) Manufacturing
CountryUS

About Halozyme Therapeutics Inc.

we are a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapies that target the tumor microenvironment. our lead proprietary program, investigational drug pegph20, applies a unique approach to targeting solid tumors, potentially providing increased tumor access for co-administered cancer therapies. by breaking down potential barriers to cancer, pegph20 may help make existing treatments more effective by allowing therapies to reach the tumor. we are built on a foundation of value-driving partnerships with leading pharmaceutical companies including, roche, pfizer, janssen, baxalta, abbvie and lilly, for our enhanze™ drug delivery technology platform, which enables biologics and small molecule compounds currently administered intravenously to be delivered subcutaneously. this technology may also allow for more rapid delivery of therapies that are already delivered subcutaneously. we are a diverse team, who are committed to bringing therapies